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Objectives: To compare the expected costs and outcomes
of seven alternative long-term primary care strategies for
the management of patients with moderate-to-severe
heartburn over a 1-year period.
Methods: A decision-analytic model was developed to
estimate costs and effects (weeks with heartburn symp-
toms and quality adjusted life years [QALYs]) for each
strategy. Meta-analyses were used to synthesize acute
treatment and maintenance studies and physician surveys
to collect information on patient management. The
impact of uncertainty on the base case results was
assessed using probabilistic sensitivity analysis. Probabil-
ity distributions were deﬁned for key model parameters
and techniques of Monte Carlo simulation were used to
draw values from these distributions. Cost-effectiveness
acceptability curves (CEACs) conditional on the mone-
tary value decision makers are willing to pay for a
symptom-free day or QALY were created for each 
strategy.
Results: In the base case, no strategy was strictly domi-
nated by any other strategy. However, two strategies
(maintenance H2-receptor antagonists [H2RA] and step-
down proton pump inhibitor [PPI]) were dominated
through principles of extended dominance. The least
costly and least effective strategy was intermittent H2RA,
while maintenance PPI was the most costly and most
effective.
Conclusions: This analysis showed that the best way of
managing patients with heartburn depends on how much
society is willing to pay to achieve health improvements.
Based on the commonly quoted threshold of $50,000 per
QALY, the optimal primary care strategy for managing
patients with moderate-to-severe heartburn symptoms is
to treat the symptoms with a PPI followed by mainte-
nance therapy with an H2RA to prevent symptomatic
recurrence.
Keywords: cost-effectiveness analysis, cost-utility analy-
sis, economic evaluation, heartburn.
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ABSTRACT
Introduction
Symptoms of gastroesophageal reﬂux disease
(GERD) are highly prevalent [1], and GERD is asso-
ciated with impaired health-related quality of life.
Furthermore, the direct and indirect costs attributed
to GERD are substantial [2,3]. Although GERD is
mostly managed in primary care, it accounts for
17% of visits to gastroenterologists [4]. Drugs used
to treat GERD are widely prescribed and impose a
signiﬁcant burden on government and private insur-
ance plans [5]. In addition, the market for over-the-
counter reﬂux remedies is substantial [6].
For the most part, clinical trials have emphasized
the healing and prevention of esophageal erosions
as the dominant metric of treatment efﬁcacy in 
the management of more severe GERD. Previous
meta-analyses have evaluated strategies to manage
erosive esophagitis [7,8], and published economic
models have evaluated acid suppressive therapies
using endoscopic end points to select patient
cohorts and/or judge treatment success [9,10].
However, the management of GERD in primary
care is guided by the presence and absence of symp-
toms, often without prior referral to a specialist for
endoscopic evaluation. Although the symptoms of
upper gastrointestinal disease are notoriously non-
speciﬁc, heartburn as a dominant complaint is pre-
© ISPOR 1098-3015/02/$15.00/312 312–328
313Cost-Effectiveness of Heartburn
dictive of underlying gastroesophageal reﬂux
[11,12].
Current Canadian guidelines endorse primary
care empiric management of uncomplicated heart-
burn without referral or prior investigation [13].
Thus, there is a need to reevaluate primary care
management approaches systematically in terms of
their effectiveness in relieving symptoms and their
overall cost-effectiveness. Strategies based on man-
aging patient symptoms bear greater relevance to
clinical practice in primary care, where the major-
ity of gastroesophageal reﬂux symptoms are
managed.
There continues to be controversy regarding the
optimal acute treatment and maintenance strategies
for managing heartburn. Although proton pump
inhibitors (PPI) are superior to H2-receptor antago-
nists (H2RA) and prokinetic agents (PK) in their
degree and speed of healing [14], they also have
higher acquisition costs. Payers and decision makers
must determine whether the additional cost of PPI
therapy is justiﬁed by its beneﬁts in relieving symp-
toms and preventing recurrence [10]. Economic
analyses based solely on heartburn symptoms have
been limited. Heudebert et al. [15] used decision
analysis to conclude that empiric treatment strate-
gies dominate strategies requiring initial investiga-
tion in the management of GERD. In treating
heartburn and acid regurgitation symptoms, an
analysis by Gerson et al. [16] found on-demand PPI
to dominate on-demand H2RA as well as mainte-
nance therapy with either H2RA or PPI. However,
the strategies compared in these studies were limited
and they did not derive efﬁcacy inputs from a sys-
tematic literature review and synthesis. In addition,
neither study employed probabilistic sensitivity
analysis to address uncertainty in model input 
parameters.
The objective of this study was to compare, over
a 1-year period, the expected costs and outcomes 
of alternative primary care strategies for the man-
agement of patients with moderate-to-severe 
heartburn. Outcomes are expressed in terms of
symptomatic recurrences averted, weeks without
heartburn and quality adjusted life years (QALYs)
over a 1-year period. Costs are expressed in 2001
Canadian dollars and calculated from the perspec-
tive of the provincial government payer for health
care. The analytic strategy for the analysis was ﬁve-
fold: 1) to identify strategies which are dominated
by others having both higher costs and worse out-
comes; 2) determine if any strategies are dominated
through principles of extended dominance; 3)
among the remaining nondominated strategies, to
estimate incremental costs, effects, QALYs, cost-
effectiveness, and cost-utility; 4) to determine the
impact of uncertainty in model input parameters on
the cost-effectiveness and cost-utility of the heart-
burn strategies; and 5) using commonly quoted
threshold values of cost per QALY, to determine the
optimal primary care management strategy for
patients with heartburn.
Methods
Overview of Model
A decision-analytic model was used to compare the
costs and effects of alternative long-term manage-
ment strategies for adult patients with moderate to
severe heartburn. Strategies varied with respect to
the ﬁrst-line therapy and the second-line therapy for
ﬁrst-line failure or symptom recurrence. The strate-
gies were initially based on a review of the litera-
ture and were then reﬁned based on responses from
two surveys sent to family physicians and gas-
troenterologists. The ﬁnalized strategies are shown
in Table 1 and are discussed below.
Strategy A: Intermittent short course H2RA. Acute
treatment with an H2RA (e.g., ranitidine 150mg
twice daily) for 4 weeks and no further treatment
with prescription medications until recurrence.
Strategy B: Intermittent long course H2RA. Acute
treatment with an H2RA (e.g., ranitidine 150mg
twice daily) for 4 weeks followed by another
4 weeks if symptoms persist, and no further
treatment with prescription medications until 
recurrence.
Strategy C: Intermittent PPI. Acute treatment with
a PPI (e.g., omeprazole 20mg or lansoprazole 30mg
once daily) for 4 weeks and no further treatment
with prescription medications until recurrence.
Strategy D: Maintenance H2RA. Acute treatment
with an H2RA (e.g., ranitidine 150mg twice daily)
for 4 weeks followed by continuous maintenance
treatment with an H2RA (same dose).
Strategy E: Maintenance PPI. Acute treatment with
a PPI (e.g., omeprazole 20mg or lansoprazole 30mg
once daily) for 4 weeks followed by continuous
maintenance treatment with a PPI (same dose).
Strategy F: Step-down maintenance H2RA. Acute
treatment with a PPI (e.g., omeprazole 20mg or
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lansoprazole 30mg once daily) for 4 weeks
followed by continuous maintenance treatment
with an H2RA (e.g., ranitidine 150mg bid).
Strategy G: Step-down maintenance PPI. Acute
treatment with a PPI (e.g., omeprazole 20mg or
lansoprazole 30mg once daily) for 4 weeks
followed by continuous maintenance treatment
with a low-dose PPI (e.g., omeprazole 10mg or
lansoprazole 15mg once daily).
Strategies A through G represent primary care
strategies (rather than single drugs) for the man-
agement of patients with heartburn where the
physician increases the dose of the drug or switches
to another drug if the patient fails to achieve symp-
tomatic relief or if symptoms recur. The logic of
patient management regarding step-up, step-down,
or drug switching is shown in Table 1. The strat-
egies differ in the initial management of symptoms
and in the maintenance therapy to prevent symptom
recurrence. However, there is a consistent logic
among the strategies with respect to assumptions
about step-up, step-down, and drug switching. For
example, failure to achieve symptomatic relief on an
H2RA leads to an attempt to heal with a PPI. Failure
to achieve symptomatic relief on regular-dose PPI
leads to either a 4-week or 8-week trial of double-
dose PPI. Regardless of the intent of initial therapy,
if symptom relief requires a double-dose PPI, it is
assumed for all strategies that maintenance therapy
Table 1 Step-up and switching algorithms conditional upon symptomatic relief and recurrence. In the absence of symptom
relief, management of initial or recurrent symptoms moves downwards along each algorithm. Maintenance treatment may be
included once relief of initial or recurrent symptoms is achieved.
Initial management Maintenance treatment Recurrence management Maintenance treatment
Strategy A: intermittent short course H2RA
1) H2RA x 4wks –––––––––––––––––––––––––––––––––> None –––––––––––––––> 1) H2RA x 4wks ––––––––––––––––> None
2) PPI x 4wks ––––––––––––––––––––––––––––––––––––> None –––––––––––––––> 2) PPI x 4wks ––––––––––––––––––> None
3) DD PPI x 4wks ––––––––––––––––––––––––––––– –––> PPI –––––––––––––––––> 3) DD PPI x 4wks ––––––––––––––> PPI
4) DD PPI x 4wks ––––––––––––––––––––––––––– ––––– 4) DD PPI x 4wks ––––––––––––––
5) Surgery 5) Surgery
Strategy B: intermittent long course H2RA 
1) H2RA x 4wks ––––––––––––––––––––––––––––––––––> None –––––––––––––––> 1) H2RA x 4wks ––––––––––––––––> None
2) H2RA x 4wks –––––––––––––––––––––––––––––––––– 2) H2RA x 4wks ––––––––––––––––
3) PPI x 4wks ––––––––––––––––––––––––––––––––––––> None –––––––––––––––> 3) PPI x 4wks ––––––––––––––––––> None
4) DD PPI x 4wks –––––––––––––––––––––––––– ––––––> PPI –––––––––––––––––> 4) DD PPI x 4wks ––––––––––––––> PPI
5) DD PPI x 4wks ––––––––––––––––––––––––––– ––––– 5) DD PPI x 4wks ––––––––––––––
6) Surgery 6) Surgery
Strategy C: intermittent PPI
1) PPI x 4wks ––––––––––––––––––––––––––––––––––––> None –––––––––––––––> 1) PPI x 4wks ––––––––––––––––––> None
2) DD PPI x 4wks –––––––––––––––––––––––––––– ––––> PPI –––––––––––––––––> 2) DD PPI x 4wks ––––––––––––––> PPI
3) DD PPI x 4wks –––––––––––––––––––––––––––– –––– 3) DD PPI x 4wks ––––––––––––––
4) Surgery 4) Surgery
Strategy D: maintenance H2RA
1) H2RA x 4wks ––––––––––––––––––––––––––––––––––
2) PPI x 4wks ––––––––––––––––––––––––––––––––––––> H2RA –––––––––––––––> 1) PPI x 4wks ––––––––––––––––––> H2RA
3) DD PPI x 4wks –––––––––––––––––––––––––– ––––––> PPI –––––––––––––––––> 2) DD PPI x 4wks ––––––––––––––> PPI
4) DD PPI x 4wks ––––––––––––––––––––––––––– ––––– 3) DD PPI x 4wks ––––––––––––––
5) Surgery 4) Surgery
Strategy E: maintenance PPI
1) PPI x 4wks ––––––––––––––––––––––––––––––––––––
2) DD PPI x 4wks ––––––––––––––––––––––––––– –––––> PPI –––––––––––––––––> 1) DD PPI x 4wks ––––––––––––––> PPI
3) DD PPI x 4wks ––––––––––––––––––––––––––– ––––– 2) DD PPI x 4wks ––––––––––––––
4) Surgery 3) Surgery
Strategy F: step-down maintenance H2RA
1) PPI x 4wks ––––––––––––––––––––––––––––––––––––> H2RA –––––––––––––––> 1) PPI x 4wks ––––––––––––––––––> H2RA
2) DD PPI x 4wks –––––––––––––––––––––––––– ––––––> PPI –––––––––––––––––> 2) DD PPI x 4wks ––––––––––––––> PPI
3) DD PPI x 4wks –––––––––––––––––––––––––– –––––– 3) DD PPI x 4wks ––––––––––––––
4) Surgery 4) Surgery
Strategy G: step-down maintenance PPI
1) PPI x 4wks ––––––––––––––––––––––––––––––––––––> LD PPI ––––––––––––––> 1) PPI x 4 wks –––––––––––––––– –> LD PPI
2) DD PPI x 4wks –––––––––––––––––––––––––– ––––––> PPI –––––––––––––––––> 2) DD PPI x 4wks ––––––––––––––> PPI
3) DD PPI x 4wks –––––––––––––––––––––––––– –––––– 3) DD PPI x 4wks ––––––––––––––
4) Surgery 4) Surgery
Abbreviations: DDPPI, double-dose proton pump inhibitor; H2RA, H2-receptor antagonist.
––>
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would be regular-dose PPI. Finally, if a patient expe-
riences a symptomatic recurrence on any mainte-
nance therapy, it is assumed that higher doses or
more effective medication would be required to
achieve symptomatic relief.
The overall model structure shown in Figure 1
uses the step-up, step-down, and switching algo-
rithms shown in Table 1. The model quantiﬁes
expected costs and outcomes for each strategy,
where expected means the sum of costs or outcomes
associated with each pathway in the model
weighted by their probability of occurring. There-
fore, total costs capture both the up-front costs of
initial drug therapy and any downstream costs 
due to maintenance therapy or the management of
symptomatic recurrence. A state-transition model
with three 4-month cycles was used to model costs
and events over a 12-month period.
Outcome Measures
The primary outcome measure used in the analysis
was QALYs over 12 months. The utility weight
attributed to a day of symptoms with heartburn
(0.82) was obtained from a study by Heudebert 
et al. [15], based on a consensus of experts using a
modiﬁed Delphi technique. Heartburn-free days
were assumed to incur no disutility for patients. 
In addition to QALYs, symptom-free weeks and
heartburn recurrences were also used as measures
of effect. Symptom-free weeks have been commonly
used for economic evaluations of gastroenterol-
ogic interventions as they combine the number of
symptom recurrences and the speed with which
symptoms are relieved.
A systematic review of published controlled clin-
ical trials was undertaken to derive pooled estimates
of symptom relief and recurrence probability for
each strategy. Studies published through January
2000 were identiﬁed from Medline, CINAHL, and
Health STAR using terms reﬂux, gastroesophageal
reﬂux, esophagitis, GERD, and heartburn. Fully
recursive reference searches were performed on 
all retrieved articles to ensure as comprehensive a
search as possible of the published literature. Study
inclusion criteria were: English language; adult 
subjects (i.e., over 16 years of age); randomized
controlled trial; single- or double-blind studies;
symptom reporting at baseline and scheduled time
intervals; and treatment of patients with at least 
one single-drug therapy. Although the presence or
absence of erosive esophagitis is used in most trials,
this was not a selection criterion.
 
Symptomatic 
heartburn 
Strategy A: Intermittent Short Course H2RA 
Strategy B: Intermittent Long Course H2RA 
Strategy C: Intermittent PPI 
Strategy D: Maintenance H2RA 
Strategy E: Maintenance PPI 
Strategy F: Step-down maintenance H2RA (PPI for 
heartburn relief; H2RA maintenance) 
Strategy G: Step-down maintenance PPI  
(PPI for heartburn relief; LD PPI maintenance) 
Relief after 4 weeks 
No relief Step-up therapy1 
Relief after 8 weeks 
No relief Step-up therapy1 
Relief after 4 weeks 
No relief Step-up therapy1 
Relief after 4 weeks 
No relief 
Step-up therapy1 
Relief after 4 weeks 
No relief Step-up therapy1 
Relief after 8 weeks 
No relief Step-up therapy1 
Relief after 4 weeks 
No relief Step-up therapy1 
0–4  MONTHS 
4–8  MONTHS 
8–12  MONTHS 
Recurrence 
No recurrence 
Step-up therapy1 
1See Table 1 
Figure 1 State transition model for the management of symptomatic heartburn.
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Symptomatic Relief Analysis
For studies meeting the inclusion criteria, the
number of patients with relief from heartburn
symptoms (deﬁned as mild or none) at each time
interval and the number of patients initially at risk
(i.e., intent-to-treat principle) were extracted. Rates
of symptomatic relief by drug regimen were esti-
mated using principles of meta-analysis applied to
data from single arms of trials pooled together.
Details of the methods for calculating rates of symp-
tomatic relief and recurrence are provided in
Table 2. Rates of heartburn relief were calculated
separately for regular-dose H2RA (e.g., ranitidine
150mg twice daily), regular-dose PPI (e.g., omepra-
zole 20mg or lansoprazole 30mg daily), and
double-dose PPI (e.g., omeprazole 40mg or lanso-
prazole 60mg daily).
Differences among rates of symptomatic relief
across drug regimens were assumed to be normally
distributed and were compared using standard Z-
scores. The formula used to compare rates of symp-
tomatic relief across drug regimens is also provided
in Table 2. Time with heartburn symptoms over the
acute relief period for each drug regimen was cal-
culated as the area under the relief curve using stan-
dard principles of mathematical integration.
Recurrence Analysis
For studies that met the inclusion criteria, we iden-
tiﬁed the number of patients initially at risk, and 
the number of patients with heartburn recurrence
(deﬁned as moderate-to-severe heartburn) at regu-
larly scheduled follow-up intervals. Methods for
calculating rates of symptomatic recurrence are pro-
vided in Table 2. Symptomatic recurrence rates were
estimated for the following: placebo (i.e., for inter-
mittent H2RA and PPI); H2RA (e.g., ranitidine 
150mg twice daily); regular-dose PPI (e.g., omepra-
zole 20mg or lansoprazole 30mg daily); low-dose
PPI (e.g., omeprazole 10mg or lansoprazole 15mg
daily). To estimate 95% conﬁdence intervals (CI), 
a random effects model was assumed around the
pooled rates of recurrence for each maintenance
therapy. Recurrence probabilities at each time inter-
val were compared across therapies using standard
Z-scores. The formula used to compare rates of
symptomatic recurrence across drug regimens is
also provided in Table 2.
Management of Initial and Recurring Symptoms
There are no published data regarding the typical
management of patients with moderate-to-severe
heartburn symptoms in primary care. Therefore, we
Table 2 Calculation of rates of symptomatic relief and recurrence. Using random effects pooled estimates of events from
single arms of RCTs, relief and recurrence rates were estimated assuming exponential and random effects [22–24] models.The
mathematical formulae used to perform the relief and recurrence analysis are:
Relief or recurrence
Ai Time point of observation for study i
ni Number of patients evaluated in study i
pI Proportion relieved/recurred at Time A for study i
Variance of proportion for study i
Weight given to observation i
Adjusted pooled relief/recurrence rates for treatment group (e.g., PPI-based regimens)
Random effects adjustments
Residual sum of squares for treatment group
k = number of studies
Estimation of variation between studies in treatment groups
Random effects adjusted weight given to observation i
Relief/recurrence rates for treatment groups
Random effects adjusted variance for treatment groups
95% conﬁdence interval of pooled relief/recurrence rates for treatment groups
Z-score for difference in pooled relief/recurrence rate between treatment groups 1 and 2Z V= -( ) +( )( )p p p p1 2 1 2* * * *
95 1 96% * . * C.I.  = + - ¥ ( )p pV
V wip * *( ) =1 S
p p* *= ¥( )S Sw wi i i
w V Si i* = ( ) +( )1 2p
S RSS C C2 1 2= -( )
C w w wi i i2 2= - ( )S S S
C k1 1= -
RSS wi i= ¥ -( )( )S p p 2
p p= ¥( )S Sw wi i1
w Vi i= ( )1 p
V ni i i= -( )[ ]p p1
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conducted two surveys, one of family physicians
and one of gastroenterologists. Physicians listed 
in Ontario in the 1998 Canadian Medical Directory
(CMD) were selected at random to participate in
the survey. A total of 100 questionnaires were
mailed out to family physicians and 65 to gas-
troenterologists. In both groups there were two
physicians listed in the CMD who were no longer
practicing. There were 55 family physician and 
48 gastroenterologist questionnaires completed and
returned for a response rate of 56% and 76%,
respectively. Since we assumed that all patients
would initially be managed by their family physi-
cian, the family physician survey responses were
used to determine initial patient management. The
gastroenterologist survey responses were used only
when the family physician indicated he/she would
make a referral.
The survey questionnaires were designed to
capture information about the management of
patients at initial presentation with heartburn
symptoms, after failure of initial therapy, and upon
recurrence of heartburn symptoms. The propor-
tions listed in the second column of Table 3 were
used to assign costs to the tests and procedures asso-
ciated with initial patient management. The third
and ﬁfth columns were used to cost tests and pro-
cedures ordered by family physicians if initial treat-
ment was not effective in relieving symptoms.
Finally, the fourth and sixth columns of Table 3
were used to cost out tests and procedures ordered
by the gastroenterologist after initial treatment
failure and upon referral from the family physician.
A summary of the ﬁndings from the surveys of
management of symptomatic heartburn recurrence
is presented in Table 4. Since physician management
of a recurrence might depend on previous diagno-
sis, we asked about tests and procedures ordered
under four different scenarios in both the family
physician and gastroenterologist questionnaires:
maintenance therapy for patients with previous
testing indicating nonerosive reﬂux disease (NE-
GERD); maintenance therapy for patients with 
previous evidence of erosive gastroesophageal
reﬂux disease (E-GERD); no maintenance therapy
for patients with previous testing indicating NE-
GERD; no maintenance therapy for patients with
previous testing indicating E-GERD.
The columns in Table 4 were used to cost out
tests and procedures ordered for symptomatic
recurrence. Which column was used for any par-
ticular recurrence depended on whether the patient
was on maintenance therapy or not, whether the
patient had a previous test indicating NE-GERD 
or E-GERD, and whether the patient was being
managed by their family physician or by a gas-
troenterologist. The proportion of symptomatic
patients with subsequent testing indicating NE-
GERD or E-GERD was estimated from a review of
heartburn relief studies. This proportion was used
as a “weight” for NE-GERD or E-GERD patients
in the model.
Unit Cost for Health Care Resources
Our primary source of drug price information is the
weighted average price per equivalent dose based on
scripts from the Intercontinental Medical Statistics
(IMS) CompuScript database over a 12-month
period ending November 2000. Weighted average
prices were determined by multiplying Ontario
Drug Beneﬁt (ODB) plan or manufacturer-speciﬁc
costs by the proportion of prescriptions for each
manufacturer. Weighted average prices were calcu-
lated separately for regular dose H2RA, regular-
dose PPI, and low-dose PPI. We also applied a
standard 10% pharmacy mark-up charge and used
a $4.11 dispensing fee for all prescriptions. These
are the maximum allowances under the ODB
program.
Physician fees for visits and procedures such as
Table 3 Summary of ﬁndings from the family physician and gastroenterologist surveys for initial patient management of heart-
burn symptoms
Failure of H2RA (%) Failure of PPI (%)
Test/procedure ordered Initial treatment (%) FP GI FP GI
CBC 25.5 21.8 37.5 25.0 39.6
Upper GI series 27.3 41.8 6.3 32.7 2.1
Upper GI endoscopy 1.8 21.8 64.6 23.1 89.6
24-hr pH study 0.0 0.0 2.1 1.9 10.4
Testing for H.pylori 16.4 27.3 4.2 34.6 4.2
Motility study 0.0 1.8 2.1 0.0 6.3
Referral to GI 0.0 5.5 — 42.3 —
Notes: FP: family physicians (n = 55).
GI: gastroenterologists (n = 48).
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endoscopy were obtained from the Ontario Sched-
ule of Beneﬁts for insured medical services [17].
Nonphysician procedure costs were obtained from
a hospital participating in the Ontario Case Costing
Project (OCCP) in southwestern Ontario [18]. Drug
prices, professional fees, and procedure unit costs
used in the analysis are presented in Table 5.
Cost-Effectiveness and Cost-Utility Analyses 
The analysis of the state-transition model provides
expected costs, expected recurrences, expected
weeks with heartburn symptoms, and expected
QALYs over a 12-month follow-up period. General
principles of cost-effectiveness analysis were applied
to these results [19]. First, it was determined
whether certain strategies were dominated by other
strategies, which had both higher costs and lower
therapeutic beneﬁts. Second, it was determined
whether any strategies were dominated through
principles of extended dominance (i.e., whether
linear combinations of other strategies can produce
the same (or greater) beneﬁt at lower (or the same)
cost). Finally, among nondominated alternatives,
incremental cost-effectiveness and cost-utility ratios
were calculated using the ratio of the difference in
cost to the difference in outcome between the two
alternatives. Beginning with the least costly strategy,
alternatives were compared with the next most
costly strategy to calculate incremental ratios. This
process produces what is referred to as efﬁcient
frontier of increasingly more costly and more effec-
tive strategies. The slope of this frontier reﬂects
incremental cost-effectiveness/utility—the addi-
tional cost at which additional units of effect/utility
can be purchased.
Probabilistic Sensitivity Analyses
The traditional approach used for handling uncer-
tainty in economic evaluations is to conduct 
deterministic sensitivity analyses of key model para-
meters where ﬁxed-point estimates of key model
parameters are valued one at a time. A recent
advance on simple sensitivity analysis is probabilis-
tic sensitivity analysis where one encodes probabil-
ity distributions rather than point estimates for key
model parameters, and one then uses Monte Carlo
simulation techniques to make random draws from
these distributions for each simulation of the model.
In this study, probability distributions were
deﬁned for three sets of key model parameters:
symptomatic relief; symptomatic recurrence;
resource use for initial symptom relief or symptom
Table 4 Summary of ﬁndings from the family physician and gastroenterologist surveys for management of symptomatic heart-
burn recurrence
Hypothetical patients assumed to be on Hypothetical patients assumed not to be on 
maintenance therapy (%) maintenance therapy (%)
Test/procedure NE-GERD E-GERD NE-GERD E-GERD
ordered FP GI FP GI FP GI FP GI
CBC 40.0 22.9 65.5 39.6 40.0 25.0 60.0 35.4
Upper GI series 20.0 2.1 18.2 0.0 18.2 2.1 16.4 0.0
Upper GI endoscopy 16.4 2.1 38.2 27.1 9.1 8.3 40.0 25.0
24-hr pH study 7.3 18.8 7.3 8.3 7.3 20.8 7.3 0.0
Test for H.pylori 43.6 6.3 41.8 2.1 38.2 4.2 32.7 2.1
Motility study 7.3 12.5 5.5 4.2 7.3 12.5 3.6 2.1
Referral to GI 12.7 — 32.7 — 12.7 — 27.3 —
Notes: FP: family physicians (n = 55).
GI: gastroenterologists (n = 48).
NE-GERD: previous testing indicated nonerosive gastroesophageal reﬂux disease.
E-GERD: previous testing indicated erosive gastroesophageal reﬂux disease.
Abbreviations: CBC, complete blood count; GI, gastrointestinal; H. pylori, Helicobacter pylori.
Table 5 Unit costs for health-care resources
Health-care resource Cost* (CDN$)
H2RA regular dose daily weighted average† 0.82
PPI regular dose daily weighted average† 2.33
PPI low dose daily weighted average† 2.13
Family physician general assessment 28.10
Gastroenterologist reassessment 38.65
CBC 4.52
Upper GI series 103.86
Upper GI endoscopy 222.72
24-hr pH study 14.53
Urea breath test for H.pylori 4.72
Motility study 99.33
Surgery (Nissen Fundoplication) 3695.60
*Including pharmacy mark-ups and physician fees where appropriate.
†Weighted average price per equivalent dose from IMS CompuScript database
(for example, for low-dose PPI, omeprazole 10 mg has 25% of the market,
lansoprazole 15 mg has 75% of the market, and pantoprazole 20 mg has less
than 1% of the market. The weighted average price would be [omeprazole
$1.75 ¥ 0.25] + [lansoprazole $2.00 ¥ 0.25] + [pantoprazole
$1.70 ¥ < 0.01] = $1.94. After adding on a standard 10% pharmacy mark-up,
the total weighted cost would be $2.13).
Abbreviations: CBC, complete blood count; GI, gastrointestinal; H. pylori,
Helicobacter pylori.
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recurrence. In decision theory, it is common to use
a Beta distribution to represent an unknown para-
meter whose value is constrained between 0 and 1
(e.g., a proportion). Therefore, we ﬁtted Beta dis-
tributions using the method of moments [20] from
the results of the meta-analyses to represent prob-
abilities for symptom relief and symptom recur-
rence. Beta distributions were also ﬁtted from the
family physician and gastroenterologist survey
responses to represent ordering of medications, tests
and procedures for initial symptomatic relief or
upon symptomatic recurrence.
Finally, since drug costs under the ODB plan are
ﬁxed across the province and only vary by strength
and supplier, we did not feel it was appropriate 
to deﬁne continuous probability distributions for
drugs. To reﬂect drug cost variability across suppli-
ers, we constructed three separate drug-price lists;
one for regular dose H2RAs, one for regular-dose
PPIs, and one for low-dose PPIs. The entries in these
price lists reﬂected actual supplier prices and the
number of entries in each list for each supplier was
weighted according to the actual number of drug
prescriptions as reported in the IMS Compuscript
database for a 12-month period ending November
2000. In the probabilistic sensitivity analysis, drug
prices were randomly selected from these weighted
price lists for each separate simulation of the model.
Acceptability Curves and Optimal 
Heartburn Management 
Using the results from the probabilistic sensitivity
analysis and the net-beneﬁt framework [21],
CEACs were derived for each strategy for different
levels, ceiling ratios, of society’s willingness to pay
per QALY. The commonly quoted threshold of
$50,000 per QALY and the range suggested by 
Laupacis et al. [22] as moderate evidence for adop-
tion of a new technology (i.e., $20,000 to $100,000
per QALY) were then used as benchmarks to deter-
mine which strategy would be considered the most
cost-effective for managing patients with moderate-
to-severe heartburn.
Results
Symptomatic Relief
Studies of heartburn symptomatic relief meeting the
study inclusion criteria are shown in Appendix A
by drug regimen. The number of patients entering
each study along with the percentage of patients
achieving symptomatic relief at weeks 2, 4, and 8
are presented. Using these relief studies and the
methods described in Table 2 for pooling across
studies, the estimated symptomatic relief probabili-
ties are presented in Table 6 by drug regimen. The
estimated symptom relief at 4 weeks is 30% for
H2RA, 65% for regular-dose PPI, and 76% for
double-dose PPI.
Recurrence Analysis
Studies reporting recurrence of moderate-to-severe
heartburn symptoms are shown in Appendix B by
drug regimen. The number of patients entering each
study and the proportions of patients with recur-
rence at 3, 6, 9, and 12 months is presented. Based
on these studies and the methods described in
Table 2 for pooling results across studies, the results
of the recurrence analysis are presented in Table 6.
These results indicate that the 3-month recurrence
rate for regular-dose PPI is the lowest at 8.6%, fol-
lowed by low-dose PPI at 16.6%, H2RA at 27.4%,
and ﬁnally, no therapy (in strategies with no main-
tenance therapy) at 50.6%. The PPI drug regimens
also have the lowest conditional 4-month recur-
rence rates (4.2 and 3.5%, respectively).
Table 6 Heartburn symptomatic relief and recurrence probabilities by drug regimen
Drug regimen No. of study arms Relief / recurrence
Symptom relief (%) at:
4 weeks (95% CI) 8 weeks* (95% CI)
H2RA 34 30.0 (25.6, 34.5) 15.7 (8.45, 23.11)
PPI regular dose 29 65.0 (60.5, 69.3) — —
PPI double dose 11 76.0 (69.0, 82.3) 12.5 (0, 45.8)
Symptom recurrence (%) at:
First 3 months (95% CI) Every 4 months† (95% CI)
Placebo 5 50.6 (45.2, 55.9) 14.8 (7.9, 22.1)
H2RA 2 27.4 (21.7, 33.5) 11.8 (7.4, 16.6)
PPI regular dose 6 8.6 (5.9, 11.6) 4.2 (2.5, 6.1)
PPI low dose 6 16.6 13.0, 20.5) 3.5 (1.3, 5.7)
*Conditional probability of symptom relief with 4 additional weeks of therapy.
†Conditional probability of symptomatic recurrence every 4 months following initial 3 months.
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Expected Costs and Outcomes
Estimates of the expected costs, expected recur-
rences, expected weeks with heartburn symptoms,
and expected QALYs, are presented in Table 7 by
treatment strategy. The intermittent H2RA strate-
gies have the lowest expected 1-year costs but also
have the highest expected number of recurrences,
expected number of weeks with heartburn symp-
toms, and the lowest QALYs. The intermittent long-
course H2RA strategy (B) is less effective than 
the short-course strategy (A) because with the short
course, a larger proportion of patients are switched
earlier to the more effective PPI treatment. Mainte-
nance PPI has the highest expected cost per patient
over 1 year but also has the lowest expected number
of recurrences, expected weeks with heartburn
symptoms, and highest QALYs.
The incremental cost-effectiveness and cost-
utility results are shown in the last two columns of
Table 7. The incremental results show the extra
annual cost of one strategy relative to another
divided by the extra beneﬁts gained by that strategy
relative to the other strategy. In the base case analy-
sis, no treatment strategy was strictly dominated 
by any other strategy, although strategies D and G
were dominated through principles of extended
dominance. Using conventional methods for analy-
sis of multiple comparisons (see methods section),
the efﬁcient frontier of management of symptomatic
heartburn is represented by strategies B, A, C, F, 
and E. Moving from strategy B to A costs an addi-
tional $26 per heartburn symptom week averted, or
$7,515 per QALY gained. Moving from strategy A
to C costs an additional $42 per symptom week
averted (or $12,206 per QALY), from strategy C to
F costs an additional $81 per symptom week
averted ($23,367 per QALY), and ﬁnally from F to
E costs an additional $341 per symptom week
averted ($98,422 per QALY).
These incremental cost-effectiveness and cost-
utility results can be displayed graphically on a
plane showing cost and effect or cost and utility
pairings. Since the utility weight for a symptom-free
day and a day of symptoms are simply scalars for
symptom days, the shape of the efﬁcient frontier
and relative positioning of pairings was the same for
both the cost-effectiveness and cost-utility analyses.
Therefore, only the cost-utility plane will be dis-
cussed. These results are shown graphically in
Figure 2 relative to strategy B. Figure 2 illustrates
that the efﬁcient frontier of management for symp-
tomatic heartburn is represented by strategies B, A,
C, F, and E. In the base case, strategies D and G are
contained within the frontier indicating extended
dominance. The slope of the line segments in
Figure 2 reﬂects the incremental cost-utility ratio, or
how much it would cost to purchase additional
QALYs.
Probabilistic Sensitivity Analysis, Acceptability Curves,
and Optimal Management
The results of the probabilistic sensitivity analysis
(i.e., 1000 Monte Carlo simulations) are shown
graphically in Figure 3. The simulation results in
Figure 3 reveal a fair amount of variation from the
base case analysis, represented by a solid line. In
fact, there are 1000 separate efﬁciency frontiers,
one associated with each separate simulation of the
model (not shown in Figure 3). The CEACs for each
strategy are presented in Figure 4. These results
suggest that for ceiling ratios below $8,000 per
QALY, strategy B has the highest probability of
being the most cost-effective. For ceiling ratios
between $8,000 and $20,000 per QALY, strategy D
is likely to be the most cost-effective. Between
$20,000 and $115,000 per QALY, strategy F is
likely to be the most cost-effective. Finally, for
ceiling ratios above $115,000 per QALY, strategy E
Table 7 Base-case expected cost, recurrences, weeks with heartburn symptoms and incremental cost-effectiveness
Expected   Expected   Expected   Incremental Incremental
1-year recurrences weeks with cost per cost per
cost per per patient heartburn Expected heartburn week QALY*
Strategy patient in 1 year symptoms QALYs averted* (CDN$) (CDN$)
B. Intermittent long course H2RA 815 0.540 11.64 0.883 — —
A. Intermittent short course H2RA 888 0.559 8.86 0.892 26† 7,515
C. Intermittent PPI 1,005 0.523 6.10 0.902 42 12,206
F. Step-down maintenance H2RA 1,076 0.301 5.21 0.905 81 23,367
E. Maintenance PPI 1,334 0.117 4.46 0.908 341 98,422
D. Maintenance H2RA 982 0.315 7.65 0.897 } Dominated throughG. Step-down maintenance PPI 1,286 0.173 4.71 0.907 extended dominance
*Relative to the next less costly nondominated strategy.Values have been rounded.
†Example calculation (888–815)/(11.64–8.86) = 26.26.
Abbreviations: DDPPI, double-dose proton pump inhibitor; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor; QALY, quality-adjusted life year.
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Figure 3 Probabilistic sensitivity analysis: incremental costs and QALYs from 1000 Monte Carlo simulations.
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is the most cost-effective. Using the threshold of
$50,000 per QALY, the optimal primary care man-
agement for patients with moderate-to-severe heart-
burn is strategy F (PPI for relief followed by H2RA
prophylaxis). In fact, strategy F remains optimal
throughout the range suggested by Laupacis et al.,
as moderate evidence for adoption of a new tech-
nology (i.e., $20,000 to $100,000 per QALY).
Discussion
A decision-analytic model was constructed to
compare the expected costs and outcomes of seven
alternative long-term management strategies for
patients presenting with moderate-to-severe heart-
burn. General principals of cost-effectiveness analy-
sis with multiple strategies were used to compare
the expected costs and outcomes of each strategy.
Using probability distributions for symptom relief,
for symptom recurrence, and rates for ordering tests
and procedures, we were able to explore the true
impact of uncertainty and joint uncertainty across
model-input parameters on expected costs and out-
comes. The results from the probabilistic simulation
analysis provide results that are both qualitatively
and quantitatively superior to results obtained from
previous studies using traditional deterministic sen-
sitivity analyses.
Of the seven strategies evaluated for the man-
agement of heartburn, none were strictly dominated
by any other strategy in the base case analysis. Con-
ventional rules for the analysis of multiple compar-
isons would lead to the conclusion that strategies D
and G should be eliminated through principles of
extended dominance (i.e., linear combinations of
other strategies), and that the efﬁcient frontier for
heartburn management is represented by strategies
B, A, C, F, and E. Results from the probabilistic sen-
sitivity analysis showed that the optimal manage-
ment strategy depends on the maximum amount
society is willing to pay to achieve health improve-
ments. In other words, there is a trade-off between
additional cost and improved health beneﬁts. Based
on the commonly quoted threshold of $50,000 per
QALY, the optimal primary care management strat-
egy is to prescribe a PPI to relieve symptoms 
followed by a H2RA to prevent symptomatic 
recurrence.
The vast majority of published economic evalu-
ations in GERD have used endoscopic end points to
select patients and/or to judge treatment success
[9,10]. However, GERD is managed primarily by
family physicians according to symptoms and often
without referral or endoscopic evaluation. Two
recent studies have focused speciﬁcally on heart-
burn-predominant GERD symptoms. One result
from our analysis is similar to the ﬁndings of
Heudebert et al. [15], who reported a cost and
QALY trade-off between intermittent H2RA and
intermittent PPI of $10,440 per QALY. This com-
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pares to our analysis where we estimate the switch
(A to C) would cost $12,206 per QALY. A major
limitation of the Heudebert analysis, which pre-
vents a more direct comparison of study ﬁndings, is
that the study omitted the commonly used step-
down strategy of PPI for symptom relief followed
by maintenance H2RA.
Our results do not support the ﬁndings of Gerson
et al. [16], who found PPI-on-demand (intermittent)
to dominate intermittent H2RA, maintenance
H2RA, and maintenance PPI strategies. The primary
reason for these discrepant ﬁndings is that Gerson
et al. assumed a lower failure rate for intermittent
PPI (42% vs. 51%), a higher failure rate for main-
tenance H2RA (50% vs. 27%), and a higher failure
rate for maintenance PPI (20% vs. 9%).
As with all modeling studies, a number of limi-
tations of the present study are noteworthy. First,
we have assumed standardized management strate-
gies for patients presenting with heartburn symp-
toms (Table 1 and Fig. 1) based on survey responses
from 55 family physicians and 48 gastroenterolo-
gists. Although physicians who participated in the
survey were randomly selected from across Ontario,
it is unclear how generalizeable their responses are.
It is likely that there are geographic differences in
practice patterns, in waiting times for specialist
referral, and in the timely availability of diagnostic
tests and procedures such as endoscopy. Second, 
for the symptom relief and symptom recurrence
meta-analyses, the majority of studies relied on
endoscopy results as a primary entry criterion and
outcome measure, and symptoms were typically a
secondary criterion. When enough symptom-based
studies are available, it would be worthwhile to
update the meta-analyses and compare the results.
Third, we used moderate-to-severe heartburn as
our primary measure of GERD symptoms. This was
primarily because of differences across studies in
how GERD symptoms are measured and which
symptoms are included in the analysis. Since heart-
burn is the predominant symptom of GERD, most
studies include a separate reporting of heartburn
symptoms. It is uncertain how the results of this
study might change if a different or more inclusive
symptom deﬁnition was used. Fourth, the 1-year
time horizon chosen for the study may be too short
to capture long-term complications such as Barrett’s
esophagus or esophageal stricture. Given the lack of
long-term follow-up studies, we did not feel it was
appropriate to extrapolate the model much beyond
1 year. Finally, this study uses inputs (i.e., costs),
which are speciﬁc to the province of Ontario. Price
weights and surveys of practice patterns from other
geographic areas would be needed to fully explore
the potential impact of regional variations in cost
and practice patterns.
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Appendix A: Studies reporting relief of moderate-to-severe heartburn symptoms
Relief at Relief at Relief at Relief at
Drug Reference N baseline (%) 2 weeks (%) 4 weeks (%) 8 weeks (%)
Cim400qid Bate, 1997 [26] 109 0 (0) 34 (31)
Cim400qid Dehn, 1990 [27] 36 1 (3) 13 (36) 17 (47) 17 (47)
Cim400qid Bate, 1990 [278] 138 15 (11) 50 (36) 51 (37)
Cim400qid Hameeteman, 1987 [29] 21 4 (19) 11 (52) 13 (62)
Cim400qid Wesdorp, 1978 [30] 12 0 (0) 5 (42)
Cim400qid Bright-Asare, 1980 [31] 20 0 (0) 11 (55) 14 (70) 15 (75)
Cim400qid Tytgat, 1987 [32] 21 4 (19) 11 (52) 13 (62)
Fam20bid Sabesin, 1991 [33] 137 1 (1) 14 (10) 19 (14) 55 (40)
Fam20bid Robinson, 1991 [34] 158 3 (2) 14 (9) 30 (19)
Fam40od Robinson, 1991 [34] 155 3 (2) 6 (4) 16 (10)
Fam40od Sabesin, 1991 [33] 135 2 (1) 10 (7) 14 (10) 41 (30)
Ran150bid Hungin, 1993 [35] 209 3 (1) 50 (24)
Ran150bid Bate, 1991 [36] 138 6 (4) 55 (40) 68 (49)
Ran150bid Londong, 1992 [37] 78 0 (0) 24 (31) 19 (24)
Ran150bid Klinkenberg-Knol, 1987 [38] 26 0 (0) 6 (23) 8 (31)
Ran150bid Vantrappen, 1988 [39] 30 0 (0) 6 (20) 9 (30)
Ran150bid Koop, 1995 [40] 83 2 (2) 36 (43) 39 (47)
Ran150bid Johnson, 1989 [41] 69 2 (3) 35 (51)
Ran150bid Bianchi Porro, 1992 [42] 30 0 (0) 6 (20) 13 (43)
Ran150bid Maton, 1999 [43] 161 0 (0) 60 (37) 71 (44)
Ran150bid Bardhan, 1999 [44] 229 0 (0) 60 (26)
Ran150bid Kahrilas, 1999 [45] 136 0 (0) 48 (35) 54 (40)
Ran150bid Bardhan, 1995 [46] 77 14 (18) 30 (39)
Ran150bid Dakkak, 1994 [47] 21 3 (14) 11 (52) 6 (29) 7 (33)
Ran150bid Havelund, 1988 [48] 82 3 (4) 30 (37)
Ran150bid Italian, 1991 [49] 86 0 (0) 41 (48)
Ran150bid Richter, 1996 [50] 97 5 (5) 11 (11) 12 (12) 38 (39)
Ran150bid Schaub, 1986 [51] 10 0 (0) 4 (40)
327Cost-Effectiveness of Heartburn
Relief at Relief at Relief at Relief at
Drug Reference N baseline (%) 2 weeks (%) 4 weeks (%) 8 weeks (%)
Ran150bid Venables, 1995 [52] 326 0 (0) 130 (40)
Ran150bid Bovero. 1987 [53] 60 5 (8) 20 (33)
Ran150bid Simon, 1987 [54] 19 1 (5) 6 (32) 16 (84)
Ran300od Johnson, 1991 [55] 138 0 (0) 50 (36) 52 (38)
Ran300od Johnson, 1991 [55] 140 0 (0) 50 (36) 61 (44)
Ran300od Bovero. 1987 [53] 57 1 (2) 20 (35)
H2RA 3244 78 (2) 192 (18) 942 (31) 622 (41)
Om20od Hungin, 1993 [35] 214 6 (3) 118 (55)
Om20od Bate, 1991 [36] 142 10 (7) 94 (66) 102 (72)
Om20od Venables, 1995 [52] 330 0 (0) 201 (61)
Om20od Galmiche, 1997 [56] 141 0 (0) 92 (65)
Om20od Hetzel, 1988 [57] 82 15 (18) 51 (62) 62 (76)
Om20od Bianchi Porro, 1992 [42] 30 0 (0) 18 (60) 20 (67)
Om20od Sontag, 1992 [58] 93 12 (13) 41 (44) 55 (59) 66 (71)
Om20od Mossner, 1995 [59] 95 0 (0) 70 (74) 81 (85)
Om20od Bate, 1993 [60] 313 13 (4) 220 (70) 115 (73)
Om20od Robinson, 1993 [61] 92 18 (20) 44 (48) 55 (60) 66 (72)
Om20od Corinaldesi, 1995 [62] 105 4 (4) 80 (76) 86 (82)
Om20od Bardhan, 1999 [44] 221 0 (0) 122 (55)
Om20od Hatlebakk, 1999 [63] 161 0 (0) 59 (37) 71 (44) 76 (47)
Om20od Bate, 1997 [26] 112 0 (0) 74 (66)
Om20od Maton, 1999 [43] 156 0 (0) 98 (63) 104 (67)
Om20od Dekkers, 1999 [64] 97 0 (0) 59 (61) 64 (66)
Om20od Bate, 1996 [65] 98 0 (0) 50 (51)
Om20od Bate, 1990 [28] 134 13 (10) 94 (70) 93 (69)
Om20od Carlsson, 1998 [66] 225 23 (10) 153 (68)
Om20od Italian, 1991 [49] 86 3 (3) 49 (57)
Om20od Laursen, 1992 [67] 110 2 (2) 70 (64) 72 (65)
Om20od Richter, 1996 [50] 100 17 (17) 33 (33) 46 (46) 74 (74)
Lan30od Robinson, 1995 [68] 23 1 (4) 14 (61)
Lan30od Bardhan, 1995 [45] 77 7 (9) 61 (79)
Lan30od Mulder, 1996 [69] 106 11 (10) 95 (90)
Rab20od Dekkers, 1999 [64] 97 0 (0) 60 (62) 66 (68)
Pan40od Mossner, 1995 [59] 191 5 (3) 121 (63) 149 (78)
Pan40od Corinaldesi, 1995 [62] 103 4 (4) 79 (77) 91 (88)
Pan40od Koop, 1995 [40] 166 5 (3) 99 (60) 127 (77)
PPI 3900 169 (4) 799 (57) 2429 (66) 932 (67)
Om40od Hetzel, 1988 [57] 82 10 (12) 60 (73) 63 (77)
Om40od Laursen, 1992 [67] 109 0 (0) 71 (65) 89 (82)
Om40od Lundell, 1990 [70] 51 4 (8) 44 (86) 46 (90)
Om40od Sontag, 1992 [58] 91 16 (18) 48 (53) 62 (68) 71 (78)
Om40od Vantrappen, 1988 [39] 31 3 (10) 22 (71) 22 (71)
Om40od Dehn, 1990 [27] 31 3 (10) 21 (68) 26 (84) 23 (74)
Om40od Havelund, 1988 [48] 80 1 (1) 61 (76)
Om40od Mulder, 1996 [69] 105 16 (15) 96 (91)
Om60od Klinkenberg-Knol, 1987 [38] 25 1 (4) 17 (68) 23 (92)
Lan60od Bardhan, 1995 [46] 25 7 (9) 54 (72)
Lan60od Robinson, 1995 [68] 25 4 (15) 22 (81)
PPI-Double 707 65 (9) 146 (64) 522 (77) 273 (80)
dose
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Appendix B: Studies reporting recurrence of moderate-to-severe heartburn symptoms
Recurrence at Recurrence at Recurrence at Recurrence at
Drug Reference N 3 months (%) 6 months (%) 9 months (%) 12 months (%)
Placebo Bate, 1995 [70] 72 27 (38) 39 (54) 47 (65) 48 (67)
Placebo Hegarty, 1997 [712] 90 32 (36) 38 (42) 49 (54)
Placebo Laursen, 1995 [72] 30 21 (70)
Placebo Robinson, 1996 [734] 55 26 (47) 26 (47) 36 (65) 36 (65)
Placebo Sontag, 1996 [75] 47 37 (79) 37 (79) 37 (79) 37 (79)
Placebo 294 143 (49) 102 (59) 158 (60) 170 (64)
R150bid Hallerback,1994 [76] 128 41 (32) 54 (42) 60 (47) 70 (55)
R150bid Hegarty, 1997 [72] 90 20 (22) 27 (30) 30 (33)
H2RA 218 61 (28) 54 (42) 87 (40) 100 (46)
L15od Gough, 1996 [77] 91 9 (10)
L15od Robinson, 1996 [74] 59 12 (20) 12 (20) 13 (22) 17 (29)
L15od Sontag, 1996 [75] 50 11 (22) 12 (24) 17 (34) 18 (36)
O10od Bate, 1995 [71] 60 5 (8) 10 (17) 11 (18) 14 (23)
O10od Hallerback,1994 [76] 133 21 (16) 37 (28) 44 (33) 51 (38)
O10od Laursen, 1995 [73] 63 20 (32)
PPI-Low dose 456 69 (19) 71 (24) 85 (28) 109 (28)
L30od Gough, 1996 [77] 6 (7)
L30od Robinson, 1996 [74] 56 3 (5) 9 (16) 17 (30) 18 (32)
L30od Sontag, 1996 [75] 49 8 (16) 9 (18) 12 (24) 17 (35)
O20od Bate, 1995 [71] 68 4 (6) 7 (10) 10 (15) 12 (18)
O20od Hallerback,1994 [76] 131 14 (11) 26 (20) 28 (21) 37 (28)
O20od Laursen, 1995 [73] 67 7 (10)
PPI-Regular dose 448 36 (10) 51 (17) 67 (22) 90 (23)
